LDLR and familial hypercholesterolemia: Monoclonal antibody inhibitors of proprotein convertase subtilisin–kexin type 9 serine protease (PCSK9), a protein that regulates the recycling of LDL receptors, have recently been approved by the FDA, EMEA, and ANVISA for primary prevention in patients with hetero- and homozygous familial hypercholesterolemia or as secondary prevention in patients with CLAD who require additional LDL-c–lowering therapy.